Global Drugs for Herpes Labialis (Oral Herpes) Market Insights, Forecast to 2025

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
Herpes Simplex Virus (HSV) is a commonly found human pathogen. Globally, an estimated 4.0 billion people are infected with Herpes Virus. The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold. About 79% of the US population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold sores. In all, close to 100 million outbreaks of cold sores occur each year in the US.

The classification of drugs for herpes labialis (oral herpes) includes valacyclovir, aciclovir, famciclovir, docosanol and other. The proportion of aciclovir in 2016 is about 17%, and the proportion of valacyclovir is about 45%.

Drugs for herpes labialis (oral herpes) are widely used though external use, oral and injection. The most proportion of drugs for herpes labialis (oral herpes) is oral, and the consumption in 2016 is about 1200 M USD.

North America is the largest consumption place, with a revenue market share nearly 36.5% in 2016. Following North America, Europe is the second largest consumption place with the revenue market share of 28.4%.

Market competition is intense. GSK, Novartis, Teva, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

The global Drugs for Herpes Labialis (Oral Herpes) market is valued at 2040 million US$ in 2018 and will reach 3030 million US$ by the end of 2025, growing at a CAGR of 5.1% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Drugs for Herpes Labialis (Oral Herpes) market based on company, product type, end user and key regions.

This report studies the global market size of Drugs for Herpes Labialis (Oral Herpes) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Drugs for Herpes Labialis (Oral Herpes) in these regions.
This research report categorizes the global Drugs for Herpes Labialis (Oral Herpes) market by top players/brands, region, type and end user. This report also studies the global Drugs for Herpes Labialis (Oral Herpes) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun Group
Hikma
Haiwang
Carmex
Cipher

Market size by Product
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Market size by End User
External Use
Oral
Injection

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Drugs for Herpes Labialis (Oral Herpes) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Drugs for Herpes Labialis (Oral Herpes) market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Drugs for Herpes Labialis (Oral Herpes) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Drugs for Herpes Labialis (Oral Herpes) submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Drugs for Herpes Labialis (Oral Herpes) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Drugs for Herpes Labialis (Oral Herpes) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions